

Plasmodium falciparum hrp2/3 deletions not identified among symptomatic subjects in the Democratic Republic of the Congo

Parr JB, Phanzu F, Mansiangi P, Kieta E, Mwandagaliwa K, Mvuama N, Landela A, Atibu J, Umesumbu Efundu S, Olenga J, Thwai KL, Morgan C, Poffley A, Mungala P, Sompwe EM, Likwela JL, Rogier E, Meshnick SR, Tshefu A, N’Siala A, Kalonji A

SANRU (Sante Rural / Global Fund) DRC NMCP Kinshasa School of Public Health US Centers for Disease Control University of North Carolina




1. Background

- Over two-thirds of all malaria diagnoses in Africa are made using rapid diagnostic tests that detect histidine rich protein 2 (HRP2).¹
- A recently described deletion mutation of the *P. falciparum* histidine-rich protein 2 and/or 3 (*pfhrp2/3*) genes allows it to escape detection by common rapid diagnostic tests (RDTs).^{2,3}
- Increasing reports from Africa indicate that parasites with this mutation are common in select locations.⁴
- We previously found a 6.4% national prevalence of *pfhrp2*-negative parasites among asymptomatic children in the DRC.⁵
- Initial hypothesis: *Pfhrp2*-deleted parasites are responsible for missed clinical cases of falciparum malaria in the DRC.

2. Methods

- Sampled **3,628 symptomatic adults and children** in the DRC from three provinces.







- Screened a **subset of 427 RDT-/microscopy+ samples** and 428 RDT+/microscopy+ controls using multiple PCR assays to detect **deletion mutations in the *pfhrp2* and *pfhrp3* genes**.⁶
- Whole-genome sequenced parasites with putative deletions based on initial PCR testing using selective whole-genome amplification and Illumina HS2500 short-read sequencing.
- Confirmed PCR and whole-genome sequencing results using Luminex HRP2 antigen testing.⁷
- Performed species-specific real-time PCR on a randomly selected **subset of 1,000 samples** to evaluate the impact of non-falciparum malaria on RDT performance.

References: 1) WHO. World Malaria Report 2015, 2) Gamboa D et al. PLOS One 2010, 3) Cheng Q et al. Malar J 2014., 4) WHO. *P. falciparum* hrp2/3 gene deletions: Conclusions and recommendations of a Technical Consultation. 2016. 5) Parr JB et al. J Infect Dis 2017, 6) Parr JB et al. Malar J 2018, 7) Rogier E et al. PLOS One 2017, 8) Baker J et al. J Infect Dis 2005.

Contact: jonathan_parr@med.unc.edu; ideelresearch.org

3. Results



4. Conclusions

- Symptomatic malaria due to *pfhrp2*- or *pfhrp3*-deleted *P. falciparum* was not observed in the DRC.
- Molecular testing for *pfhrp2/3* deletions is complex. Testing using multiple approaches improves confidence in deletion calls. PfHRP2/3 antigen testing is a useful tool.
- These findings contrast with our prior study of asymptomatic children in the DRC, raising the possibility of differences in parasite virulence and/or previously undescribed PCR inhibitors.
- Ongoing HRP2-based RDT use in the DRC is appropriate for detection of falciparum malaria.
- Symptomatic malaria due non-falciparum species is common but usually occurs in mixed infections with *P. falciparum*.

Funding: Global Fund to Fight AIDS, TB, and Malaria; Thrasher Research Fund; ASTMH-Burroughs Wellcome Fund; NIH NIAID (R01 AI132547)